Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Medios AGMEDOF 88 3-Year EBITDA Growth Rate is 16.40% as of Mar. 2026, which is 16% below its 10-year median of 19.45. GuruFocus rates MEDOF with a GF Score™ of 88/100 and a GF Value™ of $67.77. The stock has 2 warning signs investors should review. Among 106 Medical Distribution companies, Medios AG ranks better than 70.75% on this metric.
During the past 12 months, Medios AG's average EBITDA Per Share Growth Rate was 13.60% per year.
During the past 3 years, the average EBITDA Per Share Growth Rate was 16.40% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 26.90% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Medios AG was 41.50% per year. The lowest was -36.80% per year. And the median was 19.45% per year.
Medios AG (OTCPK:MEDOF) 3-Year EBITDA Growth Rate Explanation
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Medios AG 3-Year EBITDA Growth Rate Related Terms
MEDOF vs MCK, COR, CAH: 3-Year EBITDA Growth Rate Comparison
For the Medical Distribution subindustry, Medios AG's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Medios AG 3-Year EBITDA Growth Rate vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Medios AG's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Medios AG's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 16.40% mean?
Medios AG (MEDOF) has a 3-Year EBITDA Growth Rate of 16.40% as of Mar. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Medios AG and its competitors. This is 16% below median its historical median of 19.45. According to the industry distribution chart, Medios AG ranks #31 out of 106 companies in the Medical Distribution industry, placing it in the top 29.2%.
Is Medios AG's 3-Year EBITDA Growth Rate too high?
Medios AG's current 3-Year EBITDA Growth Rate of 16.40% is 16% below median its 10-year median of 19.45. The Medical Distribution industry median 3-Year EBITDA Growth Rate is 5.45. Medios AG's value of 16.40% is 200.9% above this industry median. Based on the distribution chart, Medios AG ranks #31 out of 106 companies in the Medical Distribution industry, which is above the industry midpoint. Overall, Medios AG has a GF Score™ of 88/100, reflecting its overall financial health beyond just this single metric.
How does Medios AG's 3-Year EBITDA Growth Rate compare to MCK and COR?
According to the Medical Distribution industry distribution chart, Medios AG ranks #31 out of 106 companies for 3-Year EBITDA Growth Rate. This puts Medios AG in the upper half of its industry. The industry median 3-Year EBITDA Growth Rate is 5.45. Medios AG's value of 16.40% is 200.9% above this benchmark. While the company's 10-year median is 19.45 vs. the industry median of 5.45, Medios AG has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Medical Distribution company?
The median 3-Year EBITDA Growth Rate among Medical Distribution companies is 5.45, based on 106 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Medios AG's current 3-Year EBITDA Growth Rate of 16.40% is 200.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Medios AG and its competitors. For the Medical Distribution industry, the median 3-Year EBITDA Growth Rate is 5.45 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Medios AG's current 3-Year EBITDA Growth Rate is 16.40%, which is 16% below median its own 10-year median of 19.45. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medios AG stock overvalued right now?
Medios AG (MEDOF) has a current 3-Year EBITDA Growth Rate of 16.40%. The stock's GF Value™ is $67.77, compared to a current price of $50.00 — trading 26.2% below its estimated fair value. The current 3-Year EBITDA Growth Rate is 16.40%, which is 16% below median its 10-year median of 19.45 and 200.9% above the Medical Distribution industry median of 5.45. Medios AG's overall GF Score™ is 88/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Medios AG (MEDOF), the current 3-Year EBITDA Growth Rate is 16.40% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Medios AG (MEDOF) Overvalued in 2026?
Based on GuruFocus' analysis, Medios AG stock appears to be undervalued.
The current stock price of $50.00 is trading 26.2% below its estimated GF Value™ of $67.77.
Key valuation signals for MEDOF:
3-Year EBITDA Growth Rate: 16.40% (16% below median its 10-year median of 19.45)
GF Value™: $67.77 vs. price of $50.00 (26.2% below fair value)
Industry Position: 200.9% above the Medical Distribution median (#31 of 106)
No single metric tells the full story. See the MEDOF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Medios AG is engaged as a wholesaler for pharmaceutical medicinal products. The operating segments of the company includes: Patient-Specific Therapies: This area includes the compounding of medications on behalf of pharmacies in Germany. Pharmaceautical Supply: Medios is speciality pharma supplier company in germany, producing it own production facilities, hospitals, and Pharmacies. International Business: It includes all business and activities happening in international business.
88GF Score
Get the complete analysis for MEDOF
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEDOF has been successfully added to your 
